QURE uniQure N.V.
Price Chart
Executive Summary
Two directors sold a combined ~$148K in QURE stock over the past week, with the larger June 11 cluster showing 6 directors plus the Chief Customer Officer selling a total of ~$775K at $27.06 — nearly all sales are small, pre-planned-looking dispositions in the 1.9K–2.7K share range. These sales represent ~0.05% of market cap, which is trivial and routine. The broader 7-day insider-trade picture is overwhelmingly SELL-side with no material open-market buying, but the dollar amounts are miniscule for a $1.7B biotech and likely reflect periodic stock-vesting / 10b5-1-generated sales, not a coordinated bearish signal.
Key Financial Metrics
Actionable Insight
The sale sizes are too small relative to market cap to be informative — treat as routine insider liquidity. No CEO/CFO selling and no buying signals present. Monitor the next QURE catalyst (pipeline updates for AMT-130 / Huntington's gene therapy) as the real driver; insider activity alone does not warrant action here.
Key Facts
- Insider cluster over 7 days: Chief Customer & Strategy Officer + 6 directors sold on June 11 at $27.06, total ~$775K
- June 10 director grants (13,980 shares each to multiple directors at $0) were non-cash awards — no economic signal
- All individual sales are in the $50K–$430K range; combined ~$775K is ~0.05% of $1.7B market cap
- No C-suite CEO, CFO, or COO participated in the sales — mostly Director-level disposals
- Multiple Directors simultaneously exercised options (Gut Robert: M-exercise + same-day S-sale at $26.07) consistent with cashless exercise / tax-motivated sale pattern
Financial Impact
Total insider open-market sales of ~$148K (smaller cluster) + ~$775K (June 11 cluster) = ~$923K combined, or ~0.054% of $1.7B market cap
Risk Factors
- If a larger C-suite sale emerges in the next filing window, the pattern could shift from routine to concerning
- Gene therapy clinical trial setbacks or regulatory delays remain the primary fundamental risk for QURE — insider trading does not speak to this
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1781301885155 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Insider Cluster
| $27.57 awaiting T+1 | awaiting T+1 | — | $27.57 (+0.02%) |
|
Jun 12, 2026
2d ago
|
Insider Cluster
| $27.57 awaiting T+1 | awaiting T+1 | — | $27.57 (+0.02%) |
|
Jun 12, 2026
2d ago
|
Insider Cluster
| $27.57 awaiting T+1 | awaiting T+1 | — | $27.57 (+0.02%) |
|
Jun 12, 2026
2d ago
|
Insider Cluster
| $27.57 awaiting T+1 | awaiting T+1 | — | $27.57 (+0.02%) |
|
Jun 11, 2026
3d ago
|
144
| $26.81 awaiting T+1 | awaiting T+1 | — | $27.57 (+2.85%) |
|
Jun 11, 2026
3d ago
|
144
| $26.81 awaiting T+1 | awaiting T+1 | — | $27.57 (+2.85%) |
|
Jun 11, 2026
3d ago
|
144
| $26.81 awaiting T+1 | awaiting T+1 | — | $27.57 (+2.85%) |
|
Jun 3, 2026
11d ago
|
144
| $29.88 $27.99 | ▼ −6.33% | ▼ −6.72% | $27.57 (−7.73%) |
|
May 5, 2026
5w ago
|
8-K
| $21.16 $22.82 | ▲ +7.84% | ▲ +6.46% | $27.57 (+30.29%) |
|
May 5, 2026
5w ago
|
Press Release
| $21.16 $22.82 | ▼ −7.84% | ▼ −6.46% | $27.57 (−30.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access